Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: Results from a retrospective chart review and cross-sectional survey

Alesia Sadosky, Caroline Schaefer, Rachael Mann, Felicia Bergstrom, Rebecca Baik, Bruce Parsons, Srinivas Nalamachu, Edward Nieshoff, Brett R. Stacey, Alan Anschel, Michael Tuchman

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background: The purpose of this study was to characterize the burden of illness among adult subjects with painful diabetic peripheral neuropathy (pDPN) seeking treatment in the US. Methods: This observational study recruited 112 subjects with pDPN during routine visits from general practitioner and specialist sites. Subjects completed a one-time questionnaire, which included demographics, symptom duration, health care resource use, out-of-pocket costs, employment status, and validated measures that assessed pain, functioning, sleep, anxiety and depression, health status, and productivity. Investigators completed a case report form based on a 6-month retrospective chart review to capture clinical information, pDPN-related treatments, and other pDPN-related health care resource use over the past 6 months. Annualized costs were extrapolated based on reported 6-month health care resource use. Results: The mean age of the subjects was 61.1 years, 52.7% were female, and 17.9% were in paid employment. The most common comorbid conditions were sleep disturbance/insomnia (43.8%), depressive symptoms (41.1%), and anxiety (35.7%). The mean pain severity score was 5.2 (0-10 scale), and 79.5% reported moderate or severe pain. The mean pain interference with function score was 5.0 (0-10 scale) overall, with 2.0 among mild, 5.1 among moderate, and 7.0 among severe. The mean Medical Outcomes Study sleep problems index score was 48.5 (0-100 scale). The mean health state utility score was 0.61. Among subjects employed for pay, mean overall work impairment was 43.6%. Across all subjects, mean overall activity impairment was 52.3%. In total, 81.3% were prescribed at least one medication for their pDPN; 50.9% reported taking at least one nonprescription medication. Adjusted mean annualized total direct and indirect costs per subject were $4841 and $9730, respectively. Outcomes related to pain interference with function, sleep, health status, activity impairment, prescription medication use, and direct and indirect costs were significantly worse among subjects with more severe pain (P, 0.0020). Conclusion: Subjects with pDPN exhibited high pain levels, which were associated with poor sleep, function, and productivity. Health care resource utilization in pDPN was prevalent and costs increased with greater pain severity. The burden of pDPN was greater among subjects with greater pain severity.

Original languageEnglish (US)
Pages (from-to)79-92
Number of pages14
JournalDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Volume6
DOIs
StatePublished - Feb 7 2013

Fingerprint

Cost of Illness
Diabetic Neuropathies
Peripheral Nervous System Diseases
Cross-Sectional Studies
Pain
Health Resources
Sleep
Costs and Cost Analysis
Therapeutics
Delivery of Health Care
Health Status
Anxiety
Patient Acceptance of Health Care
Depression
Sleep Initiation and Maintenance Disorders
Health Expenditures
General Practitioners
Observational Studies
Prescriptions
Research Personnel

Keywords

  • Burden of illness
  • Costs
  • Health care resource use
  • Pain assessment
  • Painful diabetic peripheral neuropathy
  • Productivity
  • Quality of life
  • Treatment patterns

ASJC Scopus subject areas

  • Pharmacology
  • Internal Medicine

Cite this

Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US : Results from a retrospective chart review and cross-sectional survey. / Sadosky, Alesia; Schaefer, Caroline; Mann, Rachael; Bergstrom, Felicia; Baik, Rebecca; Parsons, Bruce; Nalamachu, Srinivas; Nieshoff, Edward; Stacey, Brett R.; Anschel, Alan; Tuchman, Michael.

In: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 6, 07.02.2013, p. 79-92.

Research output: Contribution to journalArticle

Sadosky, Alesia ; Schaefer, Caroline ; Mann, Rachael ; Bergstrom, Felicia ; Baik, Rebecca ; Parsons, Bruce ; Nalamachu, Srinivas ; Nieshoff, Edward ; Stacey, Brett R. ; Anschel, Alan ; Tuchman, Michael. / Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US : Results from a retrospective chart review and cross-sectional survey. In: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2013 ; Vol. 6. pp. 79-92.
@article{ce858a71b73449818fa83120225a2e70,
title = "Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: Results from a retrospective chart review and cross-sectional survey",
abstract = "Background: The purpose of this study was to characterize the burden of illness among adult subjects with painful diabetic peripheral neuropathy (pDPN) seeking treatment in the US. Methods: This observational study recruited 112 subjects with pDPN during routine visits from general practitioner and specialist sites. Subjects completed a one-time questionnaire, which included demographics, symptom duration, health care resource use, out-of-pocket costs, employment status, and validated measures that assessed pain, functioning, sleep, anxiety and depression, health status, and productivity. Investigators completed a case report form based on a 6-month retrospective chart review to capture clinical information, pDPN-related treatments, and other pDPN-related health care resource use over the past 6 months. Annualized costs were extrapolated based on reported 6-month health care resource use. Results: The mean age of the subjects was 61.1 years, 52.7{\%} were female, and 17.9{\%} were in paid employment. The most common comorbid conditions were sleep disturbance/insomnia (43.8{\%}), depressive symptoms (41.1{\%}), and anxiety (35.7{\%}). The mean pain severity score was 5.2 (0-10 scale), and 79.5{\%} reported moderate or severe pain. The mean pain interference with function score was 5.0 (0-10 scale) overall, with 2.0 among mild, 5.1 among moderate, and 7.0 among severe. The mean Medical Outcomes Study sleep problems index score was 48.5 (0-100 scale). The mean health state utility score was 0.61. Among subjects employed for pay, mean overall work impairment was 43.6{\%}. Across all subjects, mean overall activity impairment was 52.3{\%}. In total, 81.3{\%} were prescribed at least one medication for their pDPN; 50.9{\%} reported taking at least one nonprescription medication. Adjusted mean annualized total direct and indirect costs per subject were $4841 and $9730, respectively. Outcomes related to pain interference with function, sleep, health status, activity impairment, prescription medication use, and direct and indirect costs were significantly worse among subjects with more severe pain (P, 0.0020). Conclusion: Subjects with pDPN exhibited high pain levels, which were associated with poor sleep, function, and productivity. Health care resource utilization in pDPN was prevalent and costs increased with greater pain severity. The burden of pDPN was greater among subjects with greater pain severity.",
keywords = "Burden of illness, Costs, Health care resource use, Pain assessment, Painful diabetic peripheral neuropathy, Productivity, Quality of life, Treatment patterns",
author = "Alesia Sadosky and Caroline Schaefer and Rachael Mann and Felicia Bergstrom and Rebecca Baik and Bruce Parsons and Srinivas Nalamachu and Edward Nieshoff and Stacey, {Brett R.} and Alan Anschel and Michael Tuchman",
year = "2013",
month = "2",
day = "7",
doi = "10.2147/DMSO.S37415",
language = "English (US)",
volume = "6",
pages = "79--92",
journal = "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy",
issn = "1178-7007",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US

T2 - Results from a retrospective chart review and cross-sectional survey

AU - Sadosky, Alesia

AU - Schaefer, Caroline

AU - Mann, Rachael

AU - Bergstrom, Felicia

AU - Baik, Rebecca

AU - Parsons, Bruce

AU - Nalamachu, Srinivas

AU - Nieshoff, Edward

AU - Stacey, Brett R.

AU - Anschel, Alan

AU - Tuchman, Michael

PY - 2013/2/7

Y1 - 2013/2/7

N2 - Background: The purpose of this study was to characterize the burden of illness among adult subjects with painful diabetic peripheral neuropathy (pDPN) seeking treatment in the US. Methods: This observational study recruited 112 subjects with pDPN during routine visits from general practitioner and specialist sites. Subjects completed a one-time questionnaire, which included demographics, symptom duration, health care resource use, out-of-pocket costs, employment status, and validated measures that assessed pain, functioning, sleep, anxiety and depression, health status, and productivity. Investigators completed a case report form based on a 6-month retrospective chart review to capture clinical information, pDPN-related treatments, and other pDPN-related health care resource use over the past 6 months. Annualized costs were extrapolated based on reported 6-month health care resource use. Results: The mean age of the subjects was 61.1 years, 52.7% were female, and 17.9% were in paid employment. The most common comorbid conditions were sleep disturbance/insomnia (43.8%), depressive symptoms (41.1%), and anxiety (35.7%). The mean pain severity score was 5.2 (0-10 scale), and 79.5% reported moderate or severe pain. The mean pain interference with function score was 5.0 (0-10 scale) overall, with 2.0 among mild, 5.1 among moderate, and 7.0 among severe. The mean Medical Outcomes Study sleep problems index score was 48.5 (0-100 scale). The mean health state utility score was 0.61. Among subjects employed for pay, mean overall work impairment was 43.6%. Across all subjects, mean overall activity impairment was 52.3%. In total, 81.3% were prescribed at least one medication for their pDPN; 50.9% reported taking at least one nonprescription medication. Adjusted mean annualized total direct and indirect costs per subject were $4841 and $9730, respectively. Outcomes related to pain interference with function, sleep, health status, activity impairment, prescription medication use, and direct and indirect costs were significantly worse among subjects with more severe pain (P, 0.0020). Conclusion: Subjects with pDPN exhibited high pain levels, which were associated with poor sleep, function, and productivity. Health care resource utilization in pDPN was prevalent and costs increased with greater pain severity. The burden of pDPN was greater among subjects with greater pain severity.

AB - Background: The purpose of this study was to characterize the burden of illness among adult subjects with painful diabetic peripheral neuropathy (pDPN) seeking treatment in the US. Methods: This observational study recruited 112 subjects with pDPN during routine visits from general practitioner and specialist sites. Subjects completed a one-time questionnaire, which included demographics, symptom duration, health care resource use, out-of-pocket costs, employment status, and validated measures that assessed pain, functioning, sleep, anxiety and depression, health status, and productivity. Investigators completed a case report form based on a 6-month retrospective chart review to capture clinical information, pDPN-related treatments, and other pDPN-related health care resource use over the past 6 months. Annualized costs were extrapolated based on reported 6-month health care resource use. Results: The mean age of the subjects was 61.1 years, 52.7% were female, and 17.9% were in paid employment. The most common comorbid conditions were sleep disturbance/insomnia (43.8%), depressive symptoms (41.1%), and anxiety (35.7%). The mean pain severity score was 5.2 (0-10 scale), and 79.5% reported moderate or severe pain. The mean pain interference with function score was 5.0 (0-10 scale) overall, with 2.0 among mild, 5.1 among moderate, and 7.0 among severe. The mean Medical Outcomes Study sleep problems index score was 48.5 (0-100 scale). The mean health state utility score was 0.61. Among subjects employed for pay, mean overall work impairment was 43.6%. Across all subjects, mean overall activity impairment was 52.3%. In total, 81.3% were prescribed at least one medication for their pDPN; 50.9% reported taking at least one nonprescription medication. Adjusted mean annualized total direct and indirect costs per subject were $4841 and $9730, respectively. Outcomes related to pain interference with function, sleep, health status, activity impairment, prescription medication use, and direct and indirect costs were significantly worse among subjects with more severe pain (P, 0.0020). Conclusion: Subjects with pDPN exhibited high pain levels, which were associated with poor sleep, function, and productivity. Health care resource utilization in pDPN was prevalent and costs increased with greater pain severity. The burden of pDPN was greater among subjects with greater pain severity.

KW - Burden of illness

KW - Costs

KW - Health care resource use

KW - Pain assessment

KW - Painful diabetic peripheral neuropathy

KW - Productivity

KW - Quality of life

KW - Treatment patterns

UR - http://www.scopus.com/inward/record.url?scp=84873689387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873689387&partnerID=8YFLogxK

U2 - 10.2147/DMSO.S37415

DO - 10.2147/DMSO.S37415

M3 - Article

C2 - 23403729

AN - SCOPUS:84873689387

VL - 6

SP - 79

EP - 92

JO - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

JF - Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

SN - 1178-7007

ER -